Attitudes towards Vaccines, Intent to Vaccinate and the Relationship with COVID-19 Vaccination Rates in Individuals with Schizophrenia.

COVID-19 attitudes schizophrenia vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
31 Jul 2022
Historique:
received: 09 06 2022
revised: 25 07 2022
accepted: 28 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Schizophrenia patients are at high risk of developing severe COVID-19 outcomes but recent evidence suggests that they are under-vaccinated. This study explored the role of potential attitudinal barriers by comparing schizophrenia patients with participants from the general population regarding COVID-19 vaccination rates, general attitudes towards vaccines, and willingness to take a COVID-19 vaccine. We conducted a cross-sectional study between April 2021 and October 2021. A total of 100 people with schizophrenia and 72 nonclinical controls were recruited. In our study, individuals with schizophrenia were under-vaccinated, despite similar general attitudes towards vaccination and higher willingness to be vaccinated against COVID-19 compared to nonclinical participants. In patients, negative attitudes toward vaccines were related to higher levels of negative psychotic symptoms and higher levels of paranoid ideation. As a whole, participants with more negative attitudes towards vaccines were less likely to be vaccinated against COVID-19 and had lower levels of trust in institutions. Vaccine hesitancy does not appear to be a major barrier for COVID-19 vaccine uptake amongst people with schizophrenia. This study suggests that disparities in COVID-19 vaccination rates in schizophrenia do not seem related to attitudinal but rather structural barriers.

Identifiants

pubmed: 36016116
pii: vaccines10081228
doi: 10.3390/vaccines10081228
pmc: PMC9414756
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de la Recherche
ID : SCHIZOVAC; ANR-21-COVR-0017

Références

J Pers Med. 2022 Jan 14;12(1):
pubmed: 35055426
Vaccine. 2021 Apr 8;39(15):2024-2034
pubmed: 33722411
Schizophr Res. 2021 May;231:49-50
pubmed: 33752107
Australas Psychiatry. 2019 Apr;27(2):171-178
pubmed: 30501496
Lancet Psychiatry. 2021 May;8(5):444-450
pubmed: 33548184
Nat Commun. 2021 Jan 4;12(1):29
pubmed: 33397962
Eur Psychiatry. 2014 Sep;29(7):449-55
pubmed: 24630742
World Psychiatry. 2021 Feb;20(1):54-55
pubmed: 33131217
Acta Psychiatr Scand. 2022 Aug;146(2):168-178
pubmed: 35322409
Int J Psychiatry Med. 2013;46(1):1-13
pubmed: 24547606
Psychol Med. 2021 Dec 17;:1-3
pubmed: 34915962
World Psychiatry. 2022 Feb;21(1):153-154
pubmed: 35015350
BJPsych Open. 2021 Aug 11;7(5):e146
pubmed: 34422295
Thorax. 2013 Feb;68(2):171-6
pubmed: 23242947
JAMA Psychiatry. 2021 Jun 1;78(6):589-590
pubmed: 33320243
BMJ Open. 2021 Aug 2;11(8):e048025
pubmed: 34341047
Schizophr Bull. 2021 Aug 21;47(5):1211-1217
pubmed: 33604657
Pharm Pract (Granada). 2021 Jan-Mar;19(1):2317
pubmed: 33828623
J Am Psychiatr Nurses Assoc. 2020 Mar/Apr;26(2):172-180
pubmed: 30866701
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Glob Health J. 2021 Mar;5(1):51-55
pubmed: 33585053
Vaccine. 2018 Nov 19;36(48):7262-7269
pubmed: 30340886
Lancet. 2020 Sep 26;396(10255):898-908
pubmed: 32919524
Schizophr Bull. 2021 Apr 29;47(3):624-634
pubmed: 33089862
Int J Environ Res Public Health. 2021 Sep 04;18(17):
pubmed: 34501932
BMJ Open. 2021 Oct 28;11(10):e055085
pubmed: 34711602
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Psychiatr Res. 2021 Nov;143:16-20
pubmed: 34438198
World Psychiatry. 2021 Feb;20(1):124-130
pubmed: 33026219
Br J Psychiatry. 2021 Jun;218(6):344-351
pubmed: 33407954
Psychol Med. 2022 Jan;52(2):251-263
pubmed: 32436485
Int J Environ Res Public Health. 2021 Sep 20;18(18):
pubmed: 34574827
Acta Neuropsychiatr. 2021 Oct;33(5):273-276
pubmed: 33998428
J Pers Soc Psychol. 1984 Dec;47(6):1191-205
pubmed: 6527214
Lancet Psychiatry. 2021 Oct;8(10):901-908
pubmed: 34364406
Ann Behav Med. 2017 Oct;51(5):652-660
pubmed: 28255934
Lancet Psychiatry. 2021 Oct;8(10):860-861
pubmed: 34416185
Eur Arch Psychiatry Clin Neurosci. 2022 Apr 30;:
pubmed: 35501605
Lancet Reg Health Eur. 2021 Feb;1:100012
pubmed: 33954296
BMC Public Health. 2021 Apr 28;21(1):818
pubmed: 33910558

Auteurs

Stéphane Raffard (S)

Laboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.
University Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.

Sophie Bayard (S)

Laboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.

Margot Eisenblaetter (M)

Laboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.

Jérôme Attal (J)

University Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.

Christelle Andrieu (C)

Pôle Psychiatrie, Centre Expert Dépression Résistante et Schizophrénie Fonda Mental, CHU La Conception, 13005 Marseille, France.
CEReSS-health Service Research and Quality of Life Center, Aix-Marseille University, 27 Boulevard Jean-Moulin, 13005 Marseille, France.

Isabelle Chereau (I)

CHU Clermont-Ferrand, Service de Psychiatrie B, Université Clermont Auvergne, 63000 Clermont-Ferrand, France.
Centre Référent de Réhabilitation Psychosociale et de Remeédiation Cognitive (C3R), CH Alpes Iseère, 38400 Saint-Martin-d'Hères, France.

Guillaume Fond (G)

Pôle Psychiatrie, Centre Expert Dépression Résistante et Schizophrénie Fonda Mental, CHU La Conception, 13005 Marseille, France.
CEReSS-health Service Research and Quality of Life Center, Aix-Marseille University, 27 Boulevard Jean-Moulin, 13005 Marseille, France.

Sylvain Leignier (S)

Centre Référent de Réhabilitation Psychosociale et de Remeédiation Cognitive (C3R), CH Alpes Iseère, 38400 Saint-Martin-d'Hères, France.

Jasmina Mallet (J)

AP-HP, Department of Psychiatry, Louis Mourier Hospital, 92700 Colombes, France.
INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris, University Paris Descartes, 75006 Paris, France.
Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, 75013 Paris, France.

Philippe Tattard (P)

University Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.

Mathieu Urbach (M)

Department of Adult Psychiatry and Addictology, Versailles Hospital, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157 Le Chesnay, France.
DisAP-DevPsy-CESP, INSERM UMR1018, University of Paris-Saclay, University of Versailles Saint-Quentin-En-Yvelines, 94807 Villejuif, France.

David Misdrahi (D)

Department of Adult Psychiatry, Charles Perrens Hospital, University of Bordeaux, Laboratory of Nutrition and Integrative Neurobiology (UMR INRA 1286), 33000 Bordeau, France.

Yasmine Laraki (Y)

Laboratory EPSYLON, Paul Valéry University Montpellier 3, CEDEX 5, 34199 Montpellier, France.
University Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.

Delphine Capdevielle (D)

University Department of Adult Psychiatry, CHU Montpellier, 34000 Montpellier, France.
IGF, University Montpellier, CNRS, INSERM, 34000 Montpellier, France.

Classifications MeSH